New Gold’s year-to-date stock performance.
New Gold: “It’s ok. I mean, why not buy Agnico Eagle? That’s the one I really, really like. They’re doing so well.”
D-Wave Quantum’s year-to-date stock performance.
Bristol-Myers Squibb’s year-to-date stock performance.
Bristol-Myers Squibb: “Never seen it this cheap. We’re holding it. I did have high hopes for…their central nervous system drug. It better work. If it doesn’t work, we’re going to get rid of it.”
CleanSpark’s year-to-date stock performance.
CleanSpark: “You can speculate with it. As long as you understand that it’s speculation and nothing more.”

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.
Disclaimer The CNBC Investing Club Charitable Trust owns shares of Bristol-Myers Squibb.
Questions for Cramer?
Call Cramer: 1-800-743-CNBC
Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money Twitter – Jim Cramer Twitter – Facebook – Instagram
Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com